Smith, Salley & Associates Gilead Sciences, Inc. Transaction History

Smith, Salley & Associates

$1.48 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$73.27 - $83.09 $4,176 - $4,736	-57 Reduced 0.56%	10,099 $818,000
Q3 2023 Oct 27, 2023	SELL	$73.94 - $80.67 $61,074 - $66,633	-826 Reduced 7.52%	10,156 $761,000
Q2 2023 Aug 04, 2023	SELL	$76.01 - $86.7 $90,299 - $102,999	-1,188 Reduced 9.76%	10,982 $846,000
Q1 2023 May 03, 2023	SELL	$77.31 - $88.08 $42,675 - $48,620	-552 Reduced 4.34%	12,170 $1.01 Million
Q4 2022 Feb 03, 2023	BUY	$62.32 - $89.47 $6,045 - $8,678	97 Added 0.77%	12,722 $1.09 Million
Q2 2022 Aug 01, 2022	BUY	$57.72 - $65.01 $49,466 - $55,713	857 Added 7.28%	12,625 $780,000
Q1 2022 May 10, 2022	SELL	$57.92 - $72.58 $2.7 Million - $3.38 Million	-46,544 Reduced 79.82%	11,768 $700,000
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $5,320 - $6,038	-82 Reduced 0.14%	58,312 $4.23 Million
Q3 2021 Nov 05, 2021	SELL	$67.69 - $73.03 $12,928 - $13,948	-191 Reduced 0.33%	58,394 $4.08 Million
Q2 2021 Aug 09, 2021	BUY	$63.47 - $69.35 $85,240 - $93,137	1,343 Added 2.35%	58,585 $4.03 Million
Q1 2021 Apr 30, 2021	BUY	$60.0 - $68.46 $706,620 - $806,253	11,777 Added 25.9%	57,242 $3.7 Million
Q4 2020 Jan 28, 2021	SELL	$56.65 - $64.55 $181,676 - $207,011	-3,207 Reduced 6.59%	45,465 $2.65 Million
Q3 2020 Nov 05, 2020	SELL	$62.1 - $78.08 $197,726 - $248,606	-3,184 Reduced 6.14%	48,672 $3.08 Million
Q2 2020 Aug 04, 2020	SELL	$72.34 - $84.0 $450,822 - $523,488	-6,232 Reduced 10.73%	51,856 $3.99 Million
Q1 2020 Apr 24, 2020	BUY	$62.63 - $80.22 $716,549 - $917,797	11,441 Added 24.53%	58,088 $4.34 Million
Q4 2019 Jan 27, 2020	SELL	$61.62 - $67.78 $171,303 - $188,428	-2,780 Reduced 5.62%	46,647 $3.03 Million
Q3 2019 Oct 30, 2019	BUY	$62.51 - $69.0 $52,258 - $57,684	836 Added 1.72%	49,427 $3.13 Million
Q2 2019 Jul 12, 2019	SELL	$61.87 - $69.38 $66,510 - $74,583	-1,075 Reduced 2.16%	48,591 $3.28 Million
Q1 2019 May 03, 2019	BUY	$62.53 - $70.05 $258,624 - $289,726	4,136 Added 9.08%	49,666 $3.23 Million
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $254,268 - $331,800	-4,200 Reduced 8.45%	45,530 $2.85 Million
Q3 2018 Nov 06, 2018	SELL	$71.28 - $78.92 $123,528 - $136,768	-1,733 Reduced 3.37%	49,730 $3.84 Million
Q2 2018 Aug 10, 2018	SELL	$64.88 - $75.68 $26,925 - $31,407	-415 Reduced 0.8%	51,463 $3.65 Million
Q1 2018 May 09, 2018	SELL	$72.84 - $88.8 $18,719 - $22,821	-257 Reduced 0.49%	51,878 $3.91 Million
Q4 2017 Feb 12, 2018	BUY	$71.15 - $83.52 $2,134 - $2,505	30 Added 0.06%	52,135 $3.74 Million
Q3 2017 Nov 02, 2017	BUY	$72.11 - $85.47 $3.76 Million - $4.45 Million	52,105	52,105 $4.22 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.1 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.07 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.71 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.56 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Salley & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Smith, Salley & Associates with notifications on news.

Account